WuXi Biologics (Cayman) Inc. (HKG: 2269)
Hong Kong
· Delayed Price · Currency is HKD 18.02
+0.12 (0.67%)
Oct 10, 2024, 4:08 PM HKT
WuXi Biologics Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 17,116 | 17,034 | 15,269 | 10,290 | 5,612 | 3,984 | Upgrade
|
| Revenue Growth (YoY) | 3.40% | 11.56% | 48.38% | 83.35% | 40.88% | 57.18% | Upgrade
|
| Cost of Revenue | 10,499 | 10,206 | 8,545 | 5,461 | 3,079 | 2,325 | Upgrade
|
| Gross Profit | 6,617 | 6,828 | 6,724 | 4,829 | 2,533 | 1,659 | Upgrade
|
| Selling, General & Admin | 2,000 | 1,789 | 1,433 | 1,001 | 605.85 | 444.37 | Upgrade
|
| Research & Development | 788.44 | 785.82 | 682.82 | 501.58 | 303.73 | 259.65 | Upgrade
|
| Other Operating Expenses | 22.33 | 23.47 | -1.49 | 24.29 | 4.95 | - | Upgrade
|
| Operating Expenses | 3,167 | 2,895 | 2,374 | 1,659 | 1,031 | 710.74 | Upgrade
|
| Operating Income | 3,450 | 3,933 | 4,350 | 3,170 | 1,502 | 947.97 | Upgrade
|
| Interest Expense | -147.74 | -158.49 | -64.38 | -39.19 | -42.73 | -19.61 | Upgrade
|
| Interest & Investment Income | 336.33 | 219.18 | 115.79 | 58.03 | 80.86 | 75.75 | Upgrade
|
| Earnings From Equity Investments | - | - | - | - | 2.63 | -3.12 | Upgrade
|
| Currency Exchange Gain (Loss) | -211.38 | 46.73 | 417.2 | -32.58 | -91.3 | 8.08 | Upgrade
|
| Other Non Operating Income (Expenses) | 199.74 | 173.38 | 159.56 | 171.36 | 142.54 | 114.04 | Upgrade
|
| EBT Excluding Unusual Items | 3,627 | 4,214 | 4,978 | 3,328 | 1,594 | 1,123 | Upgrade
|
| Gain (Loss) on Sale of Investments | 72.4 | 13.83 | 379.44 | 665.44 | 371.44 | 3.52 | Upgrade
|
| Other Unusual Items | -46.2 | -53.58 | - | - | - | - | Upgrade
|
| Pretax Income | 3,653 | 4,174 | 5,358 | 3,993 | 1,966 | 1,127 | Upgrade
|
| Income Tax Expense | 640.13 | 603.18 | 807.87 | 484.54 | 273.07 | 116.3 | Upgrade
|
| Earnings From Continuing Operations | 3,013 | 3,571 | 4,550 | 3,509 | 1,693 | 1,010 | Upgrade
|
| Minority Interest in Earnings | -380.94 | -170.9 | -129.62 | -120.1 | -3.81 | 3.47 | Upgrade
|
| Net Income | 2,632 | 3,400 | 4,420 | 3,388 | 1,689 | 1,014 | Upgrade
|
| Net Income to Common | 2,632 | 3,400 | 4,420 | 3,388 | 1,689 | 1,014 | Upgrade
|
| Net Income Growth | -36.60% | -23.09% | 30.45% | 100.63% | 66.59% | 60.77% | Upgrade
|
| Shares Outstanding (Basic) | 4,136 | 4,164 | 4,173 | 4,174 | 3,953 | 3,717 | Upgrade
|
| Shares Outstanding (Diluted) | 4,302 | 4,349 | 4,376 | 4,422 | 4,209 | 3,997 | Upgrade
|
| Shares Change (YoY) | -1.28% | -0.62% | -1.04% | 5.05% | 5.30% | 1.41% | Upgrade
|
| EPS (Basic) | 0.64 | 0.82 | 1.06 | 0.81 | 0.43 | 0.27 | Upgrade
|
| EPS (Diluted) | 0.60 | 0.77 | 1.01 | 0.77 | 0.40 | 0.25 | Upgrade
|
| EPS Growth | -36.82% | -23.50% | 31.17% | 92.50% | 60.00% | 56.25% | Upgrade
|
| Free Cash Flow | -311.97 | 622.14 | -326.72 | -3,077 | -4,144 | -2,003 | Upgrade
|
| Free Cash Flow Per Share | -0.07 | 0.14 | -0.07 | -0.70 | -0.98 | -0.50 | Upgrade
|
| Gross Margin | 38.66% | 40.08% | 44.04% | 46.93% | 45.13% | 41.64% | Upgrade
|
| Operating Margin | 20.16% | 23.09% | 28.49% | 30.81% | 26.77% | 23.80% | Upgrade
|
| Profit Margin | 15.38% | 19.96% | 28.95% | 32.93% | 30.09% | 25.45% | Upgrade
|
| Free Cash Flow Margin | -1.82% | 3.65% | -2.14% | -29.90% | -73.83% | -50.27% | Upgrade
|
| EBITDA | 4,548 | 4,928 | 5,069 | 3,622 | 1,771 | 1,141 | Upgrade
|
| EBITDA Margin | 26.57% | 28.93% | 33.20% | 35.20% | 31.56% | 28.65% | Upgrade
|
| D&A For EBITDA | 1,098 | 995.46 | 718.63 | 452.24 | 268.92 | 193.36 | Upgrade
|
| EBIT | 3,450 | 3,933 | 4,350 | 3,170 | 1,502 | 947.97 | Upgrade
|
| EBIT Margin | 20.16% | 23.09% | 28.49% | 30.81% | 26.77% | 23.80% | Upgrade
|
| Effective Tax Rate | 17.52% | 14.45% | 15.08% | 12.13% | 13.89% | 10.32% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.